After radiation therapy, certain cancer patients face a lingering question: Is a troubling lesion a return of the cancer, or ...

In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was associated ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...

Researchers from the University of Hong Kong have discovered that the Epstein-Barr virus (EBV), a common human virus closely linked to nasopharyngeal carcinoma (NPC), can change the 3D structure of ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...

Statin use during concurrent chemoradiotherapy (CCRT) for advanced nasopharyngeal cancer (NPC) is associated with a 52% reduction in all-cause mortality. Higher cumulative defined daily doses of ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma.

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274 Sixteen towns in Sihui and Zhongshan cities, China, were selected; eight were randomly ...